Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Subscribe To Our Newsletter & Stay Updated
